House panel to hold hearing over EpiPen price hikes

Published



A House investigative panel plans to hold a new hearing to grill the drug maker behind a 400 percent price hike for the life-saving allergy drug EpiPen.

The House Oversight Committee’s Sept. 21 hearing will include testimony from Mylan CEO Heather Bresch on the high price tag of $600 for EpiPens. She later lowered the price for some patients after public outcry.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.